Joint Programming Initiative on Antimicrobial Resistance

JPIAMR is undertaking an extensive mapping exercise on antimicrobial resistance (AMR) related to:

  • Research funding – visualised in the interactive tool AMR Research Funding Dashboard
  • Research projects
  • Research centers/units
  • Research infrastructure
  • Industry alliances

The aim is to enable researchers, funders and industries:

  • To determine what has already been funded across the different areas of AMR research
  • To avoid duplication and identify potential partnering opportunities and
  • To determine what is still required in order to set strategic priorities

Mapping of AMR research funding

In 2014, the JPIAMR conducted the first systematic analyses of public funding of research on antibacterial resistance. Databases of public funding organisations across 19 countries, and at EU level, were systematically searched for publicly funded antibacterial resistance research from 2007 to 2013, and categorised around the JPIAMR Strategic Research Agenda’s (SRA) six priority topics – therapeutics, diagnostics, surveillance, transmission, environment, and interventions.

We identified 1243 antibacterial resistance research projects, with a total public investment of 1.300 millon € across 19 countries and at the EU level, including public investment in the Innovative Medicines Initiative. The picture of this funding landscape guided the JPIAMR member countries and their joint investments towards future AMR research. Read more in the report on Mapping of AMR research funding (2014).

The aim of the 2017 mapping exercise was to obtain an overview of the grant investments, research capacity and scope among JPIAMR member countries for AMR research. This involved mapping of antimicrobial resistance (including anti-fungal, anti-parasitic and anti-bacterial) research undertaken in the JPIAMR member countries and research funded by the European Commission and the Wellcome Trust. We recorded a total investment of 1 794 million € from 1 939 projects in AMR, within the broad remit of the JPIAMR SRA six priority topics in the 2017 mapping. Read more in the report on Mapping of AMR research funding (2017).

Research investment seems to be better distributed to the different priority areas in the 2017 mapping rather than the one performed in 2014. The results from both the mappings highlight the need for increased investment across all member countries and also to diversify investments beyond the therapeutics area.

Graphs on mapping results 2014 and 2017Figure: Distribution of projects funded at national level per priority area of research in mapping exercise 2014 and 2017.

AMR Research Funding Dashboard

JPIAMR is utilising the organised dataset on AMR research landscape from the 2017 mapping and developed a searchable dashboard with tools allowing visual analysis of the dataset collected. It will serve as a resource for the scientific community, funders, policy makers and others to gain insight into the scale and scope of publicly funded AMR research in member countries of JPIAMR.

Go to the AMR Research Funding Dashboard.

Other resources

Excel file with AMR projects from mapping database 2014

Excel file with AMR projects from mapping database 2017

Article in the Lancet (December 2015): Public funding for research on antiabacterial resistance in the JPIAMR countries, the European Commission, and related European Union agencies – a systematic observational analysis

Mapping AMR research centres, infrastructures and industry alliances

JPIAMR has also initiated mapping exercises on AMR related to research centres/units, research infrastructures, and industry alliances.

Mapping of AMR research centres/units

AMR research is also carried out at specific research centres/units where (not all) funding is through competitive project grants. This mapping is focused on institutional funding. We will collect data regarding research centres that have significant contributions to AMR research. A dynamic network of AMR research units will provide a close contact between the JPIAMR and the scientific community and will help to build research capacity in the area of AMR. It will aim to contribute to the establishment of a Virtual Research Institute.

Mapping of AMR Research infrastructures

Limited sharing and linkage of samples, strains and data is a key barrier for AMR research. Financial and scientific investments have been committed in several member states and thousands of citizens have voluntarily contributed data and bio-specimens to biobanks and databases. Mapping of the existing AMR research infrastructure within the member states will better coordinate the databases and biobanks and will ensure effective interchange of valid information and samples. Research infrastructure mapping under the JPIAMR banner aims to harmonise resources and enhance coordination of research efforts that could be used for translational research, clinical care, personalised medicine and maximise public health benefits.

Mapping of AMR Industry alliances

Mapping of industries working in the AMR field and their specific needs will be conducted to improve data sharing and communication between academia and industry. The recent WHO review shows that the current clinical pipeline is still insufficient to mitigate the threat of antimicrobial resistance. JPIAMR has contributed to the WHO antibiotic development pipeline analyses through reviewing pipeline data and advising on the method for analyses. JPIAMR is continuing its efforts to find solutions to the challenges presented by WHO by processing current and future calls that fund research on the very challenges highlighted in the report. The full report is available here.

JPIAMR also has a specific industrial focus. It aims to address the need of developing new antibiotics by supporting small and medium-sized enterprises (SMEs). This will be realised by establishing collaboration with the BEAM Alliance (Biotech companies in Europe combating Antimicrobial Resistance) who are committed to engaging European small and medium biopharmaceutical companies involved in developing innovative products to tackle antimicrobial resistance.